India's Pharmaceutical Machine Manufacturers: From Imitation to Innovation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

India's Pharmaceutical Machine Manufacturers: From Imitation to Innovation


Pharmaceutical Technology


Marfatia's partner and Electrolab's technical director, Bharat Zaveri, describes the innovation and design needed to achieve the task. "Controlling accurate rpms was the most difficult part of creating the machine. So, we devised the AC motor controller with a feedback system and with that, the rpm was very consistent. Specification back then by the United States was ±5 rpm. We were able to create it at ±1 rpm."

Rajesh Subramaniam, managing director of Subnil Packaging Machines Ltd., satisfies the industry demand for complete tube-filling packaging lines. Subnil capitalized on this niche by manufacturing a complete packaging solution line that fills, cartons, and bundles tube products. "Now, we are the undisputed market leader in tube packaging machines in India," Subramaniam states.

Newtronic Equipment Company Pvt. Ltd. developed remote monitoring and maintenance for its stability chambers. Stability chambers are essential for determining the half-life of drugs. Director N.M. Mehta explains, "We saw the need for remote monitoring and servicing these chambers from anywhere in the world via the Internet, allowing [users] to communicate with each other from different plants so that various departments in testing facilities can better share data." Newtronic reported spending nearly 20% of their $5 million US turnover on R&D and establishing a new facility to increase production capacity. "We heavily invest in R&D and expansion to meet the demands of our continued growth," Mehta concluded.

Many IPMMs achieve innovation by reverse engineering a process or an existing solution to enhance performance and develop new applications. This technique allows them to gain a competitive advantage over other industry competitors. Dev Ashish Bakshi, joint managing partner of Tapasya Engineering Works Pvt., recalls the development of Tapasya's number one product, the "Saizoner" mixer grinder, "My father was first approached by Procter and Gamble in 1979. They asked if he could manufacture a mixer granulator if they helped with the design. My father agreed, and in a few years the engineering team developed our first Saizoner mixer grinder, which is now number one in Asia and seventh in the world."

Innovation can give a company a competitive advantage. Producing the same quality equipment for much less, however, is the main competitive advantage IPMMs have. Marfatia recalls Electrolab's first export, "After selling to Kadila Pharma, we exported our first dissolution tester. The average price of the imported one was 10,000 Euro. We sold ours for 1000 Euro, including profit."

Consequently, IPMMs carry the stigma of producing "cheap" equipment. Western manufactured equivalents are at least 10 times more expensive. "The price of the whole Indian machine could be equal to just the packaging cost of the European machine. The vast difference in price for similar equipment, in Europe or the United States, is staggering when compared with the lack of difference in the actual quality or functionality," comments an anonymous IPMMA committee member.

Perhaps the saying "you get what you pay for" does not strictly apply when comparing Indian-manufactured machines with Western-manufactured ones. Is there much of a quality difference between Indian and Western machines or are Western prices overinflated? Ipca Laboratories's managing director, Prem Godha, seems to suggest the latter. When asked whether he used Indian-manufactured pharmaceutical machines, Godha commented that 90% of his company's machines were Indian manufactured. "As an API producer, we have seen little or no difference, other than price, between Indian-made machines and their foreign competitors. Besides, we benefit more from using the Indian brands because they are nearby and can provide us with better after-sales support and service."

One can argue that Indian drug manufacturers would be biased in favor of Indian-manufactured machines, rather than foreign machines. An increasing number of foreign pharmaceutical-machine manufacturers also have recognized India's achievements and evolution in the industry.


ADVERTISEMENT

RELATED CONTENT
Bentley, Cardinal Health to Scale-Up Clinical Supplies for Intranasal Insulin
India's Pharmaceutical Machine Manufacturers: From Imitation to Innovation
Supply Chain Technology, Real-Time Quality System Win Microsoft Awards
Oral Insulin Delivery Strategies Using Absorption Promoters,
Nanoparticle Formation: A Modular High Pressure System to Enhance Biopharmaceutical Properties of Poorly Soluble Drugs
blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
18%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here